De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

ABO-incompatible heart transplantation in early childhood: An international multicenter study of clinical experiences and limits Simon Urschel, MD, Ingrid.

Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service.

Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke Michael E. Nassif, MD, Anjan Tibrewala,

Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,

An Unusual Electrocardiogram in a Heart Transplant Recipient Hamish I. MacLachlan, BSc, MBBS, Jonathan R. Dalzell, MD, MRCP The American Journal of Medicine.

Janet T. Lee, MD, Rosemary F. Kelly, MD, Marshall I

The Registry of the International Society for Heart and Lung Transplantation: Thirty- second Official Adult Lung and Heart-Lung Transplantation Report—2015;

Predictors of survival in restrictive chronic lung allograft dysfunction after lung transplantation Stijn E. Verleden, PhD, David Ruttens, MD, Elly Vandermeulen,

The Journal of Heart and Lung Transplantation

Evan P. Kransdorf, MD, PhD, Michelle M. Kittleson, MD, PhD, Jignesh K

Management of Anticoagulation in Patients with Mechanical Circulatory Support Using a Physician-Based Versus a Pharmacist Directed Anticoagulation Clinic-Based.

Patterns and Predictors of Physical Functional Disability at 5 to 10 Years After Heart Transplantation Kathleen L. Grady, PhD, RN, David C. Naftel, PhD,

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

The Journal of Heart and Lung Transplantation

The value of ventilation scintigraphy after single lung transplantation Jan Paul Ouwens, MD, Wim van der Bij, MD, PhD, Thomas W van der Mark, MD, PhD,

T. Oyaizu, S.-Y. Fung, A. Shiozaki, B. Han, S. Keshavjee, M. Liu

Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with.

Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy? Wayne C. Levy,

Jennifer A. Cowger, MD, Matthew A

Impact of initial Norwood shunt type on young hypoplastic left heart syndrome patients listed for heart transplant: A multi-institutional study Waldemar.

Low vitamin D levels are associated with increased rejection and infections after lung transplantation Erin M. Lowery, MD, Bradford Bemiss, MD, Thomas.

Manuel J. Antunes, MD, PhD, DSc

The Journal of Heart and Lung Transplantation

Boot Camp for Ventricular Assist Device Patient Recovery beyond Medical Management E.A. Hamad, V. Devlin, K. McDonnell, N. Robinson, M. Welsh, E. Kerr,

Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease:

Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score

Outcomes in highly sensitized pediatric heart transplant patients using current management strategies Alfred Asante-Korang, MD, Ernest K. Amankwah, PhD,

Injury and Illness Encountered in Shenandoah National Park

Norihisa Shigemura, MD, Jonathan D'Cunha, MD, Jay K

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

ALK FISH and IHC: You Cannot Have One without the Other

Volume 82, Issue 5, Pages (September 2012)

Postoperative Swallowing Assessment After Lung Transplantation

The effect of center volume on the incidence of postoperative complications and their impact on survival after lung transplantation Arman Kilic, MD,

Lung transplantation with donation after cardiac death donors: Long-term follow-up in a single center Nilto C. De Oliveira, MD, Satoru Osaki, MD, PhD,

The “Newbie” Syndrome Wilderness & Environmental Medicine

Exploring the Meaning of Chronic Rejection After Lung Transplantation and Its Impact on Clinical Management and Caregiving Mi-Kyung Song, PhD, RN, Annette.

B. Zane Atkins, MD, Rebecca P. Petersen, MD, MS, Mani A

The Future of Lung Transplantation

Jayme E. Locke, MD, MPH American Journal of Kidney Diseases

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

National Heart, Lung, and Blood Institute and American Association for Thoracic Surgery Workshop Report: Identifying collaborative clinical research priorities.

Phil Botha, MRCS, Dipesh Trivedi, FRCS, Christopher J

Outcomes of Intraoperative Venoarterial Extracorporeal Membrane Oxygenation Versus Cardiopulmonary Bypass During Lung Transplantation Christian A. Bermudez,

Magali P. Disdier Moulder, PharmD, PhD, Jenna M

Aditya K. Kaza, MD The Journal of Thoracic and Cardiovascular Surgery

Nasal polyposis in lung transplant recipients with cystic fibrosis

A first start for lung transplantation?

Patient Preferences in Treatment Choices for Early-Stage Lung Cancer

The ripple effect of a complication in lung transplantation: Evidence for increased long- term survival risk Ernest G. Chan, MD, Valentino Bianco, DO,

Daniel Kreisel, MD, PhD, Alexander S

Living without lungs? Bilateral pneumonectomy and dual circulatory support: A step forward in the search for a total artificial lung Christian A. Bermudez,

Society for Investigative Dermatology 2010 Meeting Minutes

Reviewer Acknowledgment

Does rituximab help in HLA desensitization for kidney transplantation?

Sara A. Hennessy, MD, Tjasa Hranjec, MD, MS, Brian R

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,

Achieving Fairness in Access to Kidney Transplant: A Work in Progress

David P. Mason, MD, Chase R. Brown, BS, Sudish C

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Effects of Prophylactic Use of Sirolimus on Bronchiolitis Obliterans Syndrome Development in Lung Transplant Recipients Vikas Y. Sacher, MD, Debra Fertel,

Susan D. Moffatt-Bruce, MD, PhD, John Karamichalis, MD, Robert C

Pitfalls in donor lung procurements: How should the procedure be taught to transplant trainees? Norihisa Shigemura, MD, Jay Bhama, MD, Duc Nguyen, MD,

Christian A. Bermudez, MD, Rodolfo V

Lung transplantation for cystic fibrosis: 6-year follow-up

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Risk factors for primary graft dysfunction after lung transplantation

Presentation transcript:

De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation Matthew R. Morrell, MD, Joseph M. Pilewski, MD, Cynthia J. Gries, MD, Matthew R. Pipeling, MD, Maria M. Crespo, MD, Christopher R. Ensor, PharmD, Samuel A. Yousem, MD, Jonathan D’Cunha, MD, Norihisa Shigemura, MD, Christian A. Bermudez, MD, John F. McDyer, MD, Adriana Zeevi, PhD The Journal of Heart and Lung Transplantation Volume 33, Issue 12, Pages 1288-1294 (December 2014) DOI: 10.1016/j.healun.2014.07.018 Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions

Figure 1 (A) Freedom from BOS in patients who developed dnDSA and those who did not develop dnDSA. (B) Freedom from high-grade BOS (Stage ≥2) in those patients who developed dnDSA and those who did not develop dnDSA. The Journal of Heart and Lung Transplantation 2014 33, 1288-1294DOI: (10.1016/j.healun.2014.07.018) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions

Figure 2 (A) Freedom from death in patients who developed dnDSA and those who did not develop DSA. (B) Freedom from death attributable to BOS in patients who developed dnDSA and those who did not develop dnDSA. The Journal of Heart and Lung Transplantation 2014 33, 1288-1294DOI: (10.1016/j.healun.2014.07.018) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions

Figure 3 (A) Freedom from BOS in patients with Class I, Class II and Class I and II dnDSA. (B) Freedom from death in patients with Class I, Class II and Class I and II dnDSA. The Journal of Heart and Lung Transplantation 2014 33, 1288-1294DOI: (10.1016/j.healun.2014.07.018) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions